TWi Biotechnology, Inc.
TWO: 6610.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chen-En Tsai
- Employees
- 21
- Headquarters
- Taipei, Taiwan
- IPO year
- 2016
- Market cap
- NT$3.0B
- Website
- https://www.twibiotech.com
Loading 6610…
Loading profile data…Frequently asked questions about 6610
What does TWi Biotechnology, Inc. (6610.TWO) do?
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes...
Where does 6610.TWO trade?
TWi Biotechnology, Inc. (6610.TWO) trades on the Taipei Exchange.
What sector is 6610.TWO in?
TWi Biotechnology, Inc. (6610.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TWi Biotechnology, Inc.?
Chen-En Tsai is the chief executive officer of TWi Biotechnology, Inc. (6610.TWO).
Where is TWi Biotechnology, Inc. headquartered?
TWi Biotechnology, Inc. is headquartered in Taiwan.
Does 6610.TWO pay a dividend?
TWi Biotechnology, Inc. (6610.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6610.TWO go public?
TWi Biotechnology, Inc. (6610.TWO) completed its initial public offering in 2016.